Rare Tumors

Rare Tumors is the premier peer-reviewed international medical journal devoted entirely to the study, diagnosis, and treatment of rare cancers. The journal covers the diagnosis, classification, and treatment of rare tumors and hematological malignancies for physicians and medical scientists interested in uncommon neoplasms. The primary intent of the journal will be to publish clinically relevant information that will directly improve the care of patients with rare cancers. Basic science studies of interest to those treating rare malignancies will also be considered for publication when relevant. A special section of the journal is dedicated to Case Reports: we would like to invite clinicians and researchers to send us their reports.

  
New Editor-in-Chief appointed
 
PAGEPress is proud to announce that Dr. Dian Wang has been appointed Editor-in-Chief of Rare Tumors. We are confident that Dr. Wang, as the new Editor-in-Chief, will be able to promote and develop the journal, making it an important point of reference for researchers in the field, continuing the excellent work done by Prof. Robert C. Miller. The staff of Rare Tumors would like to renew its thanks to the previous Editor-in-Chief and to the former Editorial Board Members for their leadership, wishing them all the best for the future research and scientific work.
  
Dr. Dian Wang is currently a Full Professor and Director of clinical research at the Department of Radiation Oncology, Rush University Medical Center, and Medical Director of Radiation Oncology at the Rush Oak Park Hospital, Chicago, IL. Also, he is a Full Professor at the Department of Urology and Co-director of Rush University Medical Center genitourinary/prostate oncology program. He has been actively working on clinical research focused on radiotherapy management of sarcoma, genitourinary/prostate malignancy, head and neck cancer and brachytherapy. Among his outstanding achievements in clinical research, his contributions to sarcoma research worth to be emphasized. Dr. Wang is an internationally-recognized radiation oncologist in treating sarcoma. He joined the NRG/RTOG Sarcoma Working Group in 2002, and served as PI for an image-guided radiotherapy for the extremity soft tissue sarcoma trial (RTOG 0630, 2007 through 2009). In addition, he has chaired the Sarcoma Working Group to conduct sarcoma research within the NRG/RTOG since 2010. He has assembled the expert team to investigate the sarcoma targeting, to establish a consensus of target volume definitions in the management of sarcoma radiotherapy, and to develop the group strategic vision on the combination of targeting agents and sarcoma radiotherapy. A series of peer reviewed manuscripts on the above projects has been published and the consensus slides and materials have been placed in the RTOG website for education. For current clinical study, Dr. Wang has co-chaired the COG AEWS1031-RTOG1172 Ewing sarcoma protocol, and the COG-NRG protocol (ARST 1321) to investigate the role of pazopanib in combination with chemoradiotherapy or radiotherapy on soft tissue sarcoma. Dr. Wang has served for the ASCO Educational Book experts panel 2015-2016, and as an advisor panelist for the Cancer.Net (www.cancer.net), ASCO’s award-winning patient education website, 2015-2017.
  

Angiosarcoma: a case report of gingival disease with both palatine tonsils... Post-transplant lymphoproliferative disorder presenting as CD20-negative... A giant phyllodes tumor of the breast Unusual ultrasound presentation of testicular metastasis from renal clear...

Vol 8, No 4 (2016)

Table of Contents

Articles
Leslie Padrnos, Nina Karlin, Thorvardur R. Halfdanarson

Abstract views: 243 | PDF: 75
Case Reports
Gautam Valecha, Dhaval Pau, Nikhil Nalluri, Ying Liu, Farhan Mohammad, Jean Paul Atallah

Abstract views: 232 | PDF: 84
Lauren Kropp, Gene P. Siegal, Garrett M. Frampton, Michael G. Rodriguez, Svetlana McKee, Robert M. Conry

Abstract views: 255 | PDF: 33
 
© PAGEPress 2008-2016     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185